Deutsch English Français

Contact

EP3017811

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3017811

EP3017811 - APIXABAN FORMULATIONS [Right-click to bookmark this link]
Status	Patent revoked Status updated on 22.03.2024 Database last updated on 11.04.2026
Former	The patent has been granted Status updated on 03.12.2018
Former	Grant of patent is intended Status updated on 30.10.2018
Former	Examination is in progress Status updated on 08.10.2018
Former	Grant of patent is intended Status updated on 20.09.2018
Former	Examination is in progress Status updated on 03.02.2017
Former	Request for examination was made Status updated on 18.11.2016
Most recent event Tooltip	22.08.2025	Change - lapse in a contracting state Updated state(s): PT	published on 24.09.2025 [2025/39]
Applicant(s)	For all designated states Bristol-Myers Squibb Holdings Ireland Unlimited Company Hinterbergstrasse 16 6312 Steinhausen / CH
	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
	[2019/14]
Former [2018/49]	For all designated states Bristol-Myers Squibb Holdings Ireland Hinterbergstrasse 16 6312 Steinhausen / CH
	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
Former [2016/32]	For all designated states Bristol-Myers Squibb Holdings Ireland Hinterbergstrasse 16 6312 Steinhausen / CH
	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
Former [2016/19]	For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08543 / US
	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
Inventor(s)	01 / PATEL, Jatin c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princton, NJ New Jersey 08543 / US
	02 / FROST, Charles c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princton, NJ New Jersey 08543 / US
	03 / JIA, Jingpin c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princton, NJ New Jersey 08543 / US
	04 / VEMA-VARAPU, Chandra c/o Bristol-Myers Squibb Company Route 206 and Province Line Road Princton, NJ New Jersey 08543 / US
	[2016/19]
Representative(s)	Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB Beselerstraße 4 22607 Hamburg / DE
	[2018/49]
Former [2016/19]	Reitstötter Kinzebach Patentanwälte Sternwartstrasse 4 81679 München / DE
Application number, filing date	15190823.3	24.02.2011
	[2016/19]
Priority number, date	US20100308056P	25.02.2010 Original published format: US 308056 P
	[2016/19]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3017811
	Date:	11.05.2016
	Language:	EN
	[2016/19]
	Type:	B1 Patent specification
	No.:	EP3017811
	Date:	05.12.2018
	Language:	EN
	[2018/49]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	03.02.2016
Classification	IPC:	A61K9/20, A61K31/4545, A61P7/02	[2016/19]
	CPC:	A61K9/14 (EP,IL,KR,RU,US); A61K31/4545 (EP,IL,KR,RU,US); A61K9/0053 (RU); A61K31/4162 (IL,US); A61K31/437 (IL,US); A61K31/4412 (IL,US); (+) A61K47/00 (RU); A61K9/16 (IL,RU,US); A61K9/20 (IL,KR,RU,US); A61K9/2013 (IL,RU,US); A61K9/2018 (EP,IL,RU,US); A61K9/2054 (EP,IL,RU,US); A61K9/2095 (EP,IL,RU,US); A61K9/48 (IL,US); A61K9/4833 (IL,US); A61P1/00 (EP,IL); A61P7/02 (EP,IL,KR,RU) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/51]
Former [2016/19]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Title	German:	APIXABAN-FORMULIERUNGEN	[2016/19]
	English:	APIXABAN FORMULATIONS	[2016/19]
	French:	FORMULATIONS D'APIXABAN	[2016/19]
Examination procedure	21.10.2015	Date on which the examining division has become responsible
	11.11.2016	Amendment by applicant (claims and/or description)
	11.11.2016	Examination requested [2016/51]
	06.02.2017	Despatch of a communication from the examining division (Time limit: M04)
	12.06.2017	Reply to a communication from the examining division
	13.09.2017	Despatch of a communication from the examining division (Time limit: M04)
	13.11.2017	Reply to a communication from the examining division
	06.09.2018	Cancellation of oral proceeding that was planned for 24.09.2018
	21.09.2018	Communication of intention to grant the patent
	24.09.2018	Date of oral proceedings (cancelled)
	28.09.2018	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	28.09.2018	Fee for grant paid
	28.09.2018	Fee for publishing/printing paid
	30.10.2018	Information about intention to grant a patent
	30.10.2018	Receipt of the translation of the claim(s)
	19.07.2022	Observations by third parties
Parent application(s) Tooltip	EP11707284.3 / EP2538925
Divisional application(s)	EP17175788.3 / EP3251660
	EP17175864.2 / EP3246021
	EP17178613.0 / EP3257500
	EP19199147.0 / EP3643301
	EP20151141.7 / EP3662899
Opposition(s)	Opponent(s)	01 27.08.2019 06.09.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. Tel Aviv 6944020 / IL Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB
		02 29.08.2019 06.09.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Kraus & Lederer PartGmbB, et al, et al Thomas-Wimmer-Ring 15 80539 München / DE
		03 30.08.2019 06.09.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 10.02.2022 WITHDRAWN KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 06.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 09.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 09.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 28.05.2021 WITHDRAWN Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 12.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
		[N/P]
	Former [2024/04]
	Opponent(s)	01 27.08.2019 06.09.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. Tel Aviv 6944020 / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 06.09.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Kraus & Weisert Patentanwälte PartGmbB, et al, et al Thomas-Wimmer-Ring 15 80539 München / DE
		03 30.08.2019 06.09.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 10.02.2022 WITHDRAWN KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 06.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 09.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 09.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 28.05.2021 WITHDRAWN Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 12.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
	Former [2022/11]
	Opponent(s)	01 27.08.2019 06.09.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. Tel Aviv 6944020 / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 06.09.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB, et al, et al Unsöldstraße 2 80538 München / DE
		03 30.08.2019 06.09.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 10.02.2022 WITHDRAWN KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 06.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 09.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 09.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 28.05.2021 WITHDRAWN Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 12.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
	Former [2021/46]
	Opponent(s)	01 27.08.2019 06.09.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St. Tel Aviv 6944020 / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 06.09.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB, et al, et al Unsöldstraße 2 80538 München / DE
		03 30.08.2019 06.09.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 06.09.2019 ADMISSIBLE KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 06.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 09.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 09.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 28.05.2021 WITHDRAWN Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 12.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
	Former [2021/27]
	Opponent(s)	01 27.08.2019 06.09.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 06.09.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB, et al, et al Unsöldstraße 2 80538 München / DE
		03 30.08.2019 06.09.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 06.09.2019 ADMISSIBLE KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 06.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 09.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 09.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 28.05.2021 WITHDRAWN Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 12.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
	Former [2021/03]
	Opponent(s)	01 27.08.2019 06.09.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 06.09.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Lederer & Keller Patentanwälte Partnerschaft mbB, et al, et al Unsöldstraße 2 80538 München / DE
		03 30.08.2019 06.09.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 06.09.2019 ADMISSIBLE KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 06.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 09.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 09.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 09.09.2019 ADMISSIBLE Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 12.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
	Former [2019/41]
	Opponent(s)	01 27.08.2019 ADMISSIBLE Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 ADMISSIBLE Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Binder, Jörg-Thomas, et al, et al Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
		03 30.08.2019 ADMISSIBLE Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE
		04 03.09.2019 ADMISSIBLE KRKA, d.d., Novo mesto Smarjeska cesta 6 8501 Novo Mesto / SI Opponent's representative Hoefer & Partner Patentanwälte mbB Pilgersheimer Straße 20 81543 München / DE
		05 03.09.2019 ADMISSIBLE ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. ul. Pelplinska 19 83-200 Starogard Gdanski / PL Opponent's representative Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB
		06 04.09.2019 ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE
		07 04.09.2019 ADMISSIBLE Zentiva, k.s. U kabelovny 130 102 37 Praha 10 - Dolni Mecholupy / CZ Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		08 04.09.2019 ADMISSIBLE Intas Pharmaceuticals Ltd. Corporate House No. Sola Bridge S. G. Highway, Thaltej Ahmedabad 380 054 / IN Opponent's representative Accord Healthcare, S.L.U. World Trade Center Moll de Barcelona s/n Edifici Est, 6ª planta 08039 Barcelona / ES
		09 05.09.2019 ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Kernebeck, Thomas Kernebeck Patentanwalts GmbH Stiftstraße 2 60313 Frankfurt am Main / DE
	Former [2019/40]
	Opponent(s)	01 27.08.2019 Teva Pharmaceutical Industries Ltd. 5 Basel Street P.O. Box 3190 49131 Petah Tiqva / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB
		02 29.08.2019 Sandoz AG Lichtstrasse 35 4056 Basel / CH Opponent's representative Binder, Jörg-Thomas, et al, et al Lederer & Keller Patentanwälte Partnerschaft mbB Unsöldstraße 2 80538 München / DE
	19.09.2019	Invitation to proprietor to file observations on the notice of opposition
	02.06.2020	Reply of patent proprietor to notice(s) of opposition
	02.11.2021	Date of oral proceedings
	01.12.2021	Despatch of minutes of oral proceedings
	01.12.2021	Despatch of communication that the patent will be revoked
	30.01.2024	Legal effect of revocation of patent [2024/17]
Appeal following opposition	25.01.2022	Appeal received No. T0212/22
	25.01.2022	Payment of appeal fee
	11.04.2022	Statement of grounds filed
	30.01.2024	Result of appeal procedure: appeal of the proprietor was rejected
	13.03.2024	Despatch of the decision of the Board of Appeal
	30.01.2024	Date of oral proceedings
Fees paid	Renewal fee
	21.10.2015	Renewal fee patent year 03
	21.10.2015	Renewal fee patent year 04
	21.10.2015	Renewal fee patent year 05
	10.02.2016	Renewal fee patent year 06
	10.02.2017	Renewal fee patent year 07
	14.02.2018	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	RS	24.02.2011
	PT	24.02.2021
	[2025/39]
Former [2025/32]	RS	24.02.2011
	PT	24.02.2023
Former [2024/34]	RS	24.02.2011
Documents cited:	Search	[IY] WO2009135947 (ATACAMA LABS OY et al.)
		[Y] US2006160841 (WEI CHENKOU et al.)
		[A] WO2007022165 (BRISTOL MYERS SQUIBB CO et al.)
		[XP] WO2010147978 (PFIZER et al.)
	Examination	WO2011106478
	by applicant	US6967208
		US2006069258
		AMIDON, G. L ET AL., PHARMACEUTICAL RESEARCH, vol. 12, 1995, pages 413 - 420
	Opposition	WO2010147978
		US2006160841
		WO2007022165
		EP2538925
		WO2011106478
		US30805610
		WO2010147978
		US2006160841
		WO2007001385
		WO2009135947
		US2006160841
		WO2010147978
		WO2011106478
		WO2008031782
		WO2010003811
		WO2010147978
		US2006160841
		WO2008031782
		WO2010003811
		WO2009135947
		WO2006108643
		US2006160841
		US2006069258
		US7396932
		WO2007022165
		WO2010147978
		US2007259913
		US6967208
		US30805610
		EP2538925
		US2009291913
		US30805610
		WO2010147978
		US2006160841
		US2009291913
		WO2009135947
		WO2007022165
		US6967208
		AMIDON, G. L. ET AL.: "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability", PHARMACEUTICAL RESEARCH, vol. 12, 1995, pages 413 - 420, XP009035978 DOI: http://dx.doi.org/10.1023/A:1016212804288
		DRESSMAN J ET AL.: "The BCS: Where Do We Go from Here?", PHARM TECH JULY, 2001, pages 68 - 76, XP055308304
		STEGEMANN ET AL.: "When poor solubility becomes an issue: From early stage to proof of concept", 2007, EUFEPSMeeting, Verona, Italy 26-27 April 2006, pages 1 - 19, XP055634955, Retrieved from the Internet DOI: http://dx.doi.org/10.1016/j.ejps.2007.05.110
		"Guidelines on the Investigation of Bioequivalence", EUROPEAN MEDICINES AGENCY, COMMITTEE OF MEDICAL PRODUCTS FOR HUMAN USE (CHMP), January 2010 (2010-01-01), pages 1 - 27, XP055308349
		YU ET AL.: "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", PHARM RES, vol. 19, 2002, pages 921 - 925, XP055308362 DOI: http://dx.doi.org/10.1023/a:1016473601633
		COOK ET AL.: "Application of the Biopharmaceutical Classification System in Clinical Drug DevelopmentAn Industrial View", THE AAPS JOURNAL, vol. 10, 2008, pages 306 - 310, XP035718954 DOI: http://dx.doi.org/10.1208/s12248-008-9036-5
		"GUIDANCE FOR INDUSTRY Waiver of In Vivo Bioavailability and Bioequivalence Studies for lmmediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", US FDA, August 2000 (2000-08-01), pages 1 - 13, XP055634962
		"Light Diffraction Measurement of Particle Aize", CHEMICAL TESTS - THE UNITED STATES PHARMACOPEIAL CONVENTION, 429, 1 May 2015 (2015-05-01), pages 294 - 299, XP055636380
		Z. STOJANOVIC ET AL.: "Determination of Particle Size Distributions by Laser Diffraction", TECHNICS - NEW MATERIALS, vol. 21, 2012, pages 11 - 20, XP055307143
		D. J. PINTO: "Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)- 4,5,6,7-tetrahydro-1 H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS- 562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", J. MED. CHEM., vol. 50, 2007, pages 5339 - 5356, XP007915445, doi:10.1021/jm070245n DOI: http://dx.doi.org/10.1021/jm070245n
		JAMES SWARBRICK: "Encyclopedia of Pharmaceutical Technology, 2nd ed.", vol. 3, 2002, article AUGSBURGER ET AL.: "Tablet Formulation", pages: 2701 - 2712, XP055308380
		L. X. YU ET AL.: "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions1", PHARMACEUTICAL RESEARCH, vol. 19, no. 7, July 2002 (2002-07-01), pages 921 - 925, XP055308362 DOI: http://dx.doi.org/10.1023/a:1016473601633
		H. H. BLUME ET AL.: "The biopharmaceutics classification system (BCS): Class III drugs better candidates for BA / BE waiver?", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 9, 1999, pages 117 - 121, XP055308358, doi:10.1016/S0928-0987(99)00076-7 DOI: http://dx.doi.org/10.1016/S0928-0987(99)00076-7
		"Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination with Antiplatelet After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial", CIRCULATION, vol. 119, no. 22, 2009, pages 2877 - 2885, XP055636386 DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.108.832139
		E. RUDNIC: "Oral Solid Dosage Forms", REMINGTON'S PHARMACEUTICAL SCIENCES, 1990, pages 1633 - 1658, XP002969032
		"Pharmazeutische Technologie, 2. Auflage", 1991, Stuttgart, article SUCKER ET AL.: "Pharmazeutische Technologie", pages: 158 - 161, XP055308164
		"Pharmazeutische Technologie", 1997, article BAUER ET AL.: "Chapter 6 and 7", pages: 178 - 208-211, XP055308166
		M. E. AULTON: "Bioavailability - physicochemical and dosage form factors", AULTON'S PHARMACEUTICS, 2007, pages 286 - 291 ; 443-449, XP055308287
		F. STORTI ET AL.: "Particle size distributions by laser diffraction: sensitivity of granular matter strength to analytical operating procedures", SOLID EARTH, vol. 1, 19 April 2010 (2010-04-19), pages 25 - 48, XP003027683, doi:10.5194/se-1-25-2010 DOI: http://dx.doi.org/10.5194/se-1-25-2010
		ANONYMOUS: "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", CLINICALTRIALS.GOV, NCT00633893, 18 February 2010 (2010-02-18), pages 1 - 4, XP055638465
		ANONYMOUS: "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", CLINICALTRIALS.GOV, NCT00643201, 18 February 2010 (2010-02-18), XP055638468
		ANONYMOUS: "A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", CLINICALTRIALS.GOV, NCT00320255, 18 February 2010 (2010-02-18), XP055638473
		"Section 2.9.31 - Particle Size Analysis by Laser Light Diffraction", EUROPEAN PHARMACOPOEIA 6.0, 23 July 2007 (2007-07-23), pages 311 - 314, XP055638472
		AMIDON ET AL.: "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", PHARMACEUTICAL RESEARCH, vol. 12, 1995, pages 413 - 420, XP055640443
		DRESSMAN ET AL.: "The BCS: Where Do We Go from Here?", PHARMACEUTICAL TECHNOLOGY, 2001, pages 68 - 76, XP055308304
		STEGEMANN ET AL.: "When poor solubility becomes an issue: From early stage to proof of concept", EUR J PHARM SCI, vol. 31, no. 5, 19 July 2007 (2007-07-19), pages 249 - 261, XP022163590 DOI: http://dx.doi.org/10.1016/j.ejps.2007.05.110
	ANONYMOUS: "<429> Light Diffraction measurement of Particle Size", US PHARMACOPOEIA, USP 38, 1 May 2015 (2015-05-01), pages 295 - 299, XP055640457
	MARCEL DEKKER: "Modern Pharmaceutics (third edition)", vol. 10, 1996, ISSN: 978-0-8247-9371-5, article E. M. RUDNIC ET AL.: "CHAPTER 10: Tablet Dosage Forms", pages: 333 - 359, XP009184716
	ANONYMOUS: "particle size analysis-laser diffraction methods", INTERNATIONAL STANDARD ISO 13320-1, 1999, pages 1 - 41, XP055512022
	"The Theory and Practice of Industrial Pharmacy", 1986, Philadelphia, article L. LACHMANN ET AL.: "The Theory and Practice of Industrial Pharmacy", pages: 221 - 222, XP055308588
	"Pharmazeutische Technologie", 1997, article K. H. BAUER ET AL.: "Pharmazeutische Technologie", pages: 209 - 210 , 365, XP055308591
	"Pharmaceutical Dissolution Testing", 1992, article U. V. BANAKAR: "Factors That Influence Dissolution Testing", pages: 136 - 137 and 144-145, XP055308585 * , Chapter Tablet Formulation, pp. 2701-2712 * * ; *
	Z. STOJANOVIC ET AL.: "Determination of particle size Distribution by laser diffraction", TECHNICS-NEW MATERIALS, vol. 21, 2012, pages 11 - 20, XP055177703
	TURPIE ALEXANDER G G: "Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases", ARTERIOSCLER THROMB VASC BIOL., vol. 27, 2007, pages 1238 - 1247, XP002672841 DOI: http://dx.doi.org/10.1161/ATVBAHA.107.139402
	AULTON M E: "Pharmaceutics The Science of Dosage Form Design, second edition", 2002, article "Pharmaceutics The Science of Dosage Form Design, second edition", pages: 23 - 29, XP055308566
	"Die Tablette Handbuch der Entwicklung, Herstellung und Qualitatssicherung", 2002, article W. A. RITSCHEL ET AL.: "Chapter 3 & 4", pages: 235 - 241 , 256-259, XP055308574
	"Pharmaceutical Dosage Forms: Tablets", vol. 1, 1989, article D. A. WADKE ET AL.: "CHAPTER 1: Preformulation Testing", pages: 1 - 9, XP009184711
	"Pharmaceutics: The Science of Dosage Form Design", vol. 1-13, 1988, article AULTON: "Biopharmaceutics", XP055640558
	ANNUAR N HAFIZAH ET AL.: "EFFECTS OF SAMPLE CONDITIONS IN MULTI-PARTICLE SIZE ANALYSIS USING LASER DIFFRACTION TECHNIQUE", SCIENTIA BRUNEIANA, vol. 11, 2010, pages 19 - 26, XP003035190
	CHRISTOPHER B GRANGER ET AL.: "The New England Journal of Medicine", N ENGL J MED, vol. 365, 2011, pages 981 - 992, XP055308595 DOI: http://dx.doi.org/10.1056/NEJMoa1107039
	"REMINGTON'S PHARMACEUTICAL SCIENCES", vol. 18, 1990, article RUDNIC E ET AL.: "ORAL SOLID DOSAGE FORMS", pages: 1633 - 1658, XP002969032
	"Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice", 2009, article "Particle, Powder, and Compact Characterization", pages: 163 - 167, XP055296127
	ANONYMOUS: "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation", CLINICALTRIALS.GOV NCT00412984, 27 September 2013 (2013-09-27), pages 1 - 7, XP055323941, Retrieved from the Internet * . (D59 of opposition proceedings against the parent patent) *
	"Definition of micronise", MERRIAM WEBSTER, pages 1, Retrieved from the Internet * . (D50 and D60 of opposition proceedings against the parent patent) *
	ANONYMOUS: "Waiver of In Vivo 012a Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", GUIDANCE FOR INDUSTRY, August 2000 (2000-08-01), pages 1 - 15, XP055640590 * . (D61 of opposition proceedings against the parent patent) *
	Y. TSUME ET AL.: "The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation", MOLECULAR PHARMACEUTICS, vol. 7, no. 4, 17 June 2010 (2010-06-17), pages 1235 - 1243, XP055308518 * . (D62 of opposition proceedings against the parent patent) *
	"European Pharmacopoeia 6.5", 2008, article ANONYMOUS, pages: 4759 - 4765, XP055640607 * (D65 of opposition proceedings against the parent patent) *
	"Pharmaceutics: The Science of Dosage Form Design", 1988, article AULTON: "tableting", pages: 647 - 653, XP055570217 * (D66 of opposition proceedings against the parent patent) *
	ANONYMOUS: "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", CLINICALTRIALS.GOV ARCHIVE, VIEW OF NCT00633893, 18 February 2010 (2010-02-18), pages 1 - 4, XP055638465 * (D67 of opposition proceedings against the parent patent) *
	"A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", CLINICALTRIALS.GOV ARCHIVE, VIEW OF NCT00643201, 18 February 2010 (2010-02-18), pages 1 - 4, XP055638468
	ANONYMOUS: "A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", CLINICALTRIALS.GOV ARCHIVE, VIEW OF NCT00320255, 18 February 2010 (2010-02-18), pages 1 - 2, XP055638473
	M. R. LASSEN ET AL.: "Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 361, 2009, pages 594 - 604, XP055308399 DOI: http://dx.doi.org/10.1056/NEJMoa0810773
	C. FROST ET AL.: "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. THROMB. HAEMOST, vol. 5, no. 2, 2007, XP055640220
	ANONYMOUS: "European Pharmacopoeia 6.0", 23 July 2007, THE STATIONERY OFFICE, article "2.9.31. PARTICLE SIZE ANALYSIS BY LASER LIGHT DIFFRACTION", pages: 311 - 314, XP055638472
	Z. STOJANOVIC ET AL.: "Determination of Particle Size by Laser Diffraction", TECHNICS - NEW MATERIALS, vol. 21, 2012, pages 11 - 20, XP055177703
	LEPIC K. ET AL.: "New Anticoagulants for the Prevention of Thromboembolism", CURRENT PHARMACEUTICAL DESIGN, vol. 16, no. 31, 1 October 2010 (2010-10-01), pages 3472 - 3474, XP055308375 DOI: http://dx.doi.org/10.2174/138161210793563437
	FROST, C. ET AL.: "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. THROMB. HAEMOST, 9 July 2007 (2007-07-09), XP055640220
	"Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism", CLINICALTRIALS.GOV NCT00633893, 18 February 2010 (2010-02-18), XP055640663, Retrieved from the Internet
	"Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism", CLINICAL TRIALS.GOV, NCT00643201, 18 February 2010 (2010-02-18), XP055640665, Retrieved from the Internet
	"A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", CLINICALTRIALS.GOV, NCT00320255, 18 February 2010 (2010-02-18), XP055638473, Retrieved from the Internet
	J. B. DRESSMAN ET AL.: "Absorption potential: Estimating the Fraction Absorbed for Orally Administered", JPHARMSCI, vol. 74, no. 5, 1 May 1985 (1985-05-01), pages 588 - 589, XP055308397, DOI: 10.1002/jps.2600740523 DOI: http://dx.doi.org/10.1002/jps.2600740523
	H.A. LIEBERMANN ET AL.: "Pharmaceutical Dosage Forms. 2nd ed.", vol. 1, 1989, article "Preformulation Testing", pages: 1 - 24, XP055640656
	ANONYMOUS: "The Biopharmaceutics Classification System (BCS) Guidance", FDA, 13 September 2016 (2016-09-13), XP055308403, Retrieved from the Internet
	D. J. P . PINTO ET AL.: "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", J. MED CHEM, vol. 50, January 2007 (2007-01-01), pages 5339 - 5356, XP007915445, DOI: 10.1021/jm070245n DOI: http://dx.doi.org/10.1021/jm070245n
	BLUME ET AL.: "The biopharmaceutics classification system (BCS): Class III drugs better candidates for BA/BE waiver?", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 9, no. 2, 1 December 1999 (1999-12-01), pages 117 - 121, XP055308358 DOI: http://dx.doi.org/10.1016/S0928-0987(99)00076-7
	AMIDON ET AL.: "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, July 1995 (1995-07-01), pages 413 - 420, XP009035978 DOI: http://dx.doi.org/10.1023/A:1016212804288
	YU ET AL.: "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", PHARMACEUTICAL RESEARCH, vol. 19, no. 7, 1 July 2002 (2002-07-01), pages 921 - 925, XP055308362 DOI: http://dx.doi.org/10.1023/a:1016473601633
	EMEA: "Committee of Medicinal Products for Human Use, Guidelines on the investigation of bioequivalence", EUROPEAN MEDICINES AGENCY CPMP/EWP/QWP/1401/98 REV. 1, 20 January 2010 (2010-01-20), pages 1 - 27, XP055640670, Retrieved from the Internet
	GIBALDI M.: "Biopharmaceutics and Clinical Pharmacokinetics", vol. 51, 1991, LEA & FEBIGER, article "Surface Area and Particle Size", XP055640673 * , Chapter Tablet Formulation, pp. 2701-2712 * * ; *
	REMINGTON: "Remington, The Science and Practice of Pharmacy", vol. 595, 1995, article "Dissolution", XP055282825
	LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", vol. 221, 1987, LEA & FEBIGER, article "Factor affecting drug absorption", XP055640678
	GILBERT S BANKER ET AL: "Tablet Dosage Forms", vol. 24, 1989, MARCEL DEKKER, article RUDNIC ET AL.: "CHAPTER 10: Tablet Dosage Forms", pages: 333 - 359, XP009184716
	BANAKAR U. V.: "Pharmaceutical Dissolution Testing", 1992, MARCEL DEKKER, article "Polymorphism", pages: 136, 137, 144 - 145, XP055641322
	BAUER K. H. ET AL.: "Pharmazeutische Technologie", 1997, GUSTAV FISCHER VERLAG, ISBN: 978-3-437-25630-0, article "Lslichkeit", pages: 209 - 210, 365, XP055641330
	AMIDON ET AL.: "Developing solid oral dosage forms: Pharmaceutical Theory and Practice", 2009, ACADEMIC PRESS, article "Chapter 8", pages: 163 - 167, 414-416, XP055641338
	SUCKER ET AL.: "Pharmazeutische Technologie", 1991, GEORG THIEME VERLAG, article "3.4.2 Feste Arzneiformen", pages: 158 - 161, XP055640651
	AULTON M.: "Pharmaceuticals- The Science of Dosage Form Design", 2007, CHURCHILL LIVINGSTONE, article "Bioavailability - physicochemical and dosage form factors", pages: 286- 291, 443 - 449, XP055308287
	SWARBRICK ET AL.: "Encyclopedia of Pharmaceutical Technology", 2002, MARCEL DEKKER, ISBN: 978-0-8247-2824-3, article "Tablet Formulation", pages: 2701 - 2712, XP055308380
	STEGEMANN ET AL.: "When poor solubility becomes an issue: From early stage to proof of concept", EUR J PHARM SCI, vol. 31, no. 5, 19 July 2007 (2007-07-19), pages 249 - 261, XP022163590 DOI: http://dx.doi.org/10.1016/j.ejps.2007.05.110

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.